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1. Introduction
Epilepsy, characterized by recurrent, spontaneous, and 
unprovoked seizures, afflicts 3.5–7.2 out of every 1000 
children (1). Although the majority of epilepsy patients 
can attain seizure-free status under the appropriate drug 
regime, approximately 10%–20% of patients will continue 
to have seizures despite treatment with widely effective 
antiepileptic drugs (AEDs).  
Medically refractory epilepsy is defined as inadequate 
seizure control despite therapy with at least 3 AEDs 
at maximally tolerated doses for 1–2 years (2). The 
identification of risk factors for intractability in childhood 
epilepsy has become a major research focus, but very few 
data exist for the Turkish population (3,4).
We performed a retrospective case-control study in 
Turkish children and adolescents with epilepsy to identify 
early predictors (at the time of initial diagnosis) associated 
with later intractable epilepsy.
2. Materials and methods
The study included children from 1 month old to 18 
years of age. All were diagnosed with epilepsy by the 
same epileptologist (FA) and antiepileptic drug therapy 
was initiated at the Başkent University Hospital in 
Ankara, Turkey, between March 2000 and March 2008. 
Medical records were reviewed to retrieve the following 
information: sex, age at onset of seizures, initial seizure 
type, initial seizure frequency, history of febrile/neonatal 
seizures, history of status epilepticus, perinatal history, 
neurodevelopmental and cognitive status, family 
history of seizure disorders, parental consanguinity, 
neurological abnormalities, brain imaging findings, 
electroencephalography (EEG) records, and etiology. This 
study was approved by the local research ethics committee.
Twenty-one–channel EEG was performed in all 
patients for the diagnosis and classification of epilepsy, and 
1.5-T magnetic resonance imaging (MRI) was used for 
routine evaluation of all patients presenting with seizures. 
We evaluated the drug treatment efficacy for each 
patient and selected a group showing poor response 
and another group exhibiting well-controlled epilepsy. 
Statistical comparisons were used to identify early 
predictors of intractability. In this study, we excluded 
children whose seizures were poorly controlled but had 
low serum drug concentrations or poor compliance.
Aim: In this retrospective study, we evaluated the clinical responses to antiepileptic drug (AED) therapy in pediatric epilepsy patients 
treated at a single center.
Materials and methods: We identified 28 children with intractable epilepsy and 213 patients with drug-responsive epilepsy.
Results: Univariate analysis showed that age at onset, high (daily) initial seizure frequency, infantile spasm, history of neonatal seizures, 
abnormal neurodevelopmental status, neurological abnormalities, mental retardation, remote symptomatic etiology, and abnormal 
brain imaging results were significant risk factors for the development of intractable epilepsy (P < 0.05). Multivariate logistic regression 
analysis revealed that high (daily) initial seizure frequency and remote symptomatic etiology were significant and independent risk 
factors for intractable epilepsy (P < 0.05).
Conclusion: Our study suggests that the risk of developing intractable epilepsy in childhood may be predicted, to some extent, by the 
early clinical course. Early identification of patients at high risk of developing intractable epilepsy will guide appropriate therapy and 
reduce exposure to ineffectual treatments.
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2.1. Definitions
Epilepsy syndromes were classified according to the 
International League Against Epilepsy (ILAE) classification 
(5). Seizures were classified according to ILAE definitions 
based on clinical descriptions and EEG recordings.
The definition of intractable epilepsy was at least 1 
seizure per month over an observation period of 1 year, 
despite medical therapy with 3 or more AEDs in maximally 
tolerated doses administered singly or in combination. 
Any drug used acutely to treat breakthrough seizure or 
status epilepticus in the emergency department was not 
counted as 1 of the 3 AEDs. The control group consisted of 
children with well-controlled epilepsy defined as at least 1 
seizure-free year at the last follow-up.
Mental retardation was diagnosed on the basis of 
clinical estimation supplemented by neuropsychological 
evaluation when available. Neuroimaging findings were 
classified as normal, abnormal, or incidental. Etiologic 
determination was divided into 3 categories: idiopathic, 
symptomatic, and cryptogenic epilepsy. Symptomatic 
epilepsy was defined as seizures associated with an 
identifiable pathology in the brain. Cryptogenic epilepsy 
was presumed to be nongenetic and a consequence of an 
underlying but undetermined lesion. Idiopathic epilepsies 
were presumed to be genetic in origin and the diagnosis 
was based on clinical and EEG findings.
History of status epilepticus was defined as at least 
1 prolonged seizure lasting more than 30 min, or a series 
of shorter seizures extending over 30 min or more during 
which time the child never fully regained consciousness (6).
Potential predictive factors tested included age at 
onset, initial seizure type, initial seizure frequency 
before treatment, history of febrile seizures, history of 
neonatal seizures and status epilepticus, perinatal history, 
neurodevelopmental delay, family history of seizure 
disorders, parental consanguinity, neurological deficits, 
mental retardation, abnormal brain imaging findings, and 
etiology.
2.2. Data analysis
Data were analyzed with SPSS 15.0 for Windows (SPSS, 
Chicago, IL, USA). Categorical variables were analyzed 
by chi-square and chi-square test trend univariate 
comparison. P < 0.05 was considered significant. Odds 
ratios (ORs) and 95% confidence intervals (CIs) were 
calculated from the estimated individual cell probabilities. 
Forward logistic multivariate regression was used to test 
candidate risk factors.
3. Results
During the retrospective study period (2000–2008), 28 
pediatric patients were treated who met our definition 
for intractable drug-refractory epilepsy (35.7% female, 
mean age ± SD: 9.90 ± 5.07 years; 64.3% male, 7.39 ± 5.19 
years). For comparison, 213 patients were included with 
well-controlled seizures (42.7% female, 8.21 ± 4.49 years; 
57.3% male, 7.40 ± 4.43 years). There was no significant 
difference in sex ratio or age between the 2 groups. The 
mean duration of follow-up was 2.6 ± 1.4 years for the 
drug-responsive patients and 3.1 ± 1.6 years for the drug-
resistant (intractable) group. 
The demographic characteristics of patients with well-
controlled and intractable epilepsy are presented in Table 
1.
A much smaller fraction of patients in the intractable 
group had an idiopathic etiology (10.7%) compared to the 
well-controlled group (64.8%) (Table 1). The proportions 
in each etiological category are shown in Table 1, while the 
specific causes of symptomatic epilepsy are presented in 
Table 2. 
A history of status epilepticus and febrile seizures, 
family history of seizure disorders, and parental 
consanguinity were not found to be significant predictors 
of intractable epilepsy in our study (P > 0.5).
On univariate analysis, age at onset of younger than 1 
year (OR = 2.057, 95% CI 1.491–2.838), high (daily) initial 
seizure frequency (OR = 9.994, 95% CI 3.419–29.209), 
positive history of neonatal seizures (OR =5.128, 95% 
CI 1.845–14.285), developmental delay (OR = 8.6, 95% 
CI 3.63–20.4), mental retardation (OR = 9.803, 95% CI 
3.921–24.390), symptomatic epilepsy (OR = 14.285, 95% 
CI 4.048–50), abnormal brain imaging results (OR = 4.76, 
95% CI 2.044–10.989), and infantile spasms (OR = 15.151, 
95% CI 2.873–76.923) were found to be significant risk 
factors in the intractable group (P < 0.05) (Table 3).
On multivariate analysis, high (daily) initial 
seizure frequency (OR = 8.2, 95% CI 2.48–26.99) and 
symptomatic etiology (OR = 12.345, 95% CI 3.3–45.45) 
were independent predictors of intractability (Table 4).
4. Discussion
There is no widely accepted definition for drug-refractory 
epilepsy. Current working definitions usually stipulate 
unresponsiveness to a number of AEDs within a specified 
treatment duration, so it is difficult to identify intractability 
in infants and very young children (7).
The reported prevalence of epilepsy varies by region in 
Turkey, from 6.10 to 10.20 per 1000 (8), but there are no 
reliable estimates of the number of Turkish children with 
intractable epilepsy. Therefore, we conducted a statistical 
analysis of candidate risk factors for intractable epilepsy at 
a central treatment facility in Turkey.
Early identification of children at high risk of 
developing intractable epilepsy is critical for parental 
counseling and for selecting the most promising 
treatments. The timely selection of an effective alternative 
will prevent the adverse effects of recurrent seizures on 
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Table 1. The demographic characteristics of patients.
Intractable
n (%)
Well-controlled
n(%) Total
Sex
Female 10 (35.7) 91 (42.7) 101
Male 18 (64.3) 122 (57.3) 140
Age at onset (years)
0–1 17 (60.7) 41 (19.3) 58
1–3 4 (14.3) 22 (10.3) 26
3–5 3 (10.7) 27 (12.76) 30
5–10 2 (7.1) 72 (33.8) 74
10–18 2 (7.1) 51 (23.9) 53
Type of seizures
Gen./tonic/clonic/tonic-clonic 13 (46.4) 83 (38.9) 96
Myoclonic 5 (17.9) 16 (7.5) 21
Partial 4 (14.3) 72 (33.8) 76
Absence 0 19 (8.9) 19
Atonic 3 (10.7) 23 (10.8) 26
Multiple 3 (10.7) 0 3
Initial seizure frequency
Daily 17 (60.7) 33 (15.5) 50
1–4/monthly 5 (17.9) 97 (45.5) 102
1–4/year 5 (17.9) 57 (26.8) 62
<1/year 1 (3.6) 26 (12.2) 27
History of febrile seizure 1 (3.6) 33 (15.5) 34
History of status epilepticus 3 (10.7) 17 (7.9) 20
Neonatal seizures 7 (25) 13 (6.1) 20
Infantile spasms 4 (14.3) 8 (3.7) 12
Consanguinity 2 (7.1) 39 (18.3) 41
Family history of seizures 5 (17.9) 27 (12.7) 32
Abnormal neurologic examination 19 (67.9) 44 (20.7) 63
Mental retardation 21 (75) 50 (23.5) 71
Developmental delay                  19 (67.9) 42 (19.7) 61
Brain imaging (MRI)
Abnormal 14 (50) 41 (19.3) 55
Normal 12 (42.8) 167 (78.4) 179
Incidental 2 (7.1) 5 (2.34) 7
Etiology
Symptomatic 18 (64.3) 58 (27.2) 76
Cryptogenic 7 (25) 17 (7.9) 24
Idiopathic 3 (10.7) 138 (64.8) 141
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behavior and intellectual development. Furthermore, early 
predictors of drug-refractory epilepsy will eliminate the 
chance of AED overdose and drug interactions resulting 
from polypharmacy.
There are few widely recognized factors predictive of 
drug-refractoriness. We analyzed a multitude of candidates 
by comparing intractable and drug-responsive cases of 
childhood epilepsy. 
Table 2. Symptomatic etiology of epilepsy in intractable and well-controlled patients. 
Etiology Intractablen (%)
Well-controlled
n (%) Total
Perinatal 9 (50) 24 (41.4) 33
Vascular 0 2 (3.4) 2
Trauma 0 2 (3.4) 2
Stroke 2 (11.1) 11 (19) 13
Hypoglycemia 0 3 (5.2) 3
CNS  infection 2 (11.1) 5 (8.6) 7
Chromosomal 0 3(5.2) 3
Neurocutaneous disease 2 (11.1) 2 (3.4) 4
Cortical dysplasia 1 (5.6) 2 (3.4) 3
Metabolic disease 1 (5.6) 2 (3.4) 3
Mesial temporal sclerosis 1 (5.6) 2 (3.4) 3
Table 3. Univariate comparison of the intractable and well-controlled groups.
Intractable
n (%)
Well-controlled
n (%) Odds ratio 95% CI P
Time of first seizure 0-1 17 (60.7) 41 (19.3) 2.057 1.491–2.838 <0.001
Initial frequency Daily 17 (60.7) 33 (15.5) 9.994 3.419–29.209 <0.001
Neonatal seizures 7 (25) 13 (6.1) 5.128 1.845–14.285 <0.001
Infantile spasm 4 (14.3) 8 (3.7) 15.151 2.873–76.923 <0.001
Abnormal neurologic examination 19 (67.9) 44 (20.7) 8.13 3.44–19.23 <0.001
Mental retardation 21 (75) 50 (23.5) 9.803 3.921–24.390 <0.001
Developmental delay 19 (67.9) 42 (19.7) 8.6 3.63–20.4 <0.001
Brain imaging (MRI) Abnormal 14 (50) 41 (19.3) 4.76 2.044–10.989 <0.001
Etiology Symptomatic 18 (64.3) 58 (27.2) 14.285 4.048–50 <0.001
Table 4. Multivariate analysis for predictor factors of intractable epilepsy.
Intractable
n (%)
Well controlled
n (%) Odds ratio 95% CI P
Initial seizure frequency Daily 17 (60.7) 33 (15.5) 8.2 2.48–26.99 <0.001
Etiology Symptomatic 18 (64.3) 58 (27.2) 12.345 3.3–45.45 <0.001
494
SAYGI et al. / Turk J Med Sci
A significant finding was that more than half of the 
patients with intractable epilepsy had daily seizures at 
onset. Both univariate and multivariate analysis revealed 
a strong positive association between daily initial seizures 
and intractability, again in accord with previous studies 
(2,4,9–11). Symptomatic etiology was another significant 
factor influencing the drug response of our epileptic 
patients. The majority of patients in the intractable group 
(64.28%) had a symptomatic etiology, whereas the majority 
of patients in the well-controlled group had an idiopathic 
etiology.
In this study, 60.7% of intractable patients exhibited an 
age at onset of less than 1 year as compared to only 19.3% 
of drug-responsive patients. Age at onset of seizures was 
an even stronger predictive factor with increasing age, 
consistent with previous reports (2,4,9,10).
Several candidate factors associated with intractability 
in previous studies were either not associated with 
intractability in our study or were significant only under 
univariate analysis. In the intractable group, 46.4% of 
first seizures were generalized tonic-clonic/tonic/clonic 
compared to 38.9% in the well-treated group, indicating 
that initial seizure type had no predictive value. Camfield et 
al. (12) reported comparable results, whereas other studies 
concluded that myoclonic seizures, multiple seizure types, 
and atypical absence seizures were associated with the 
poorest drug responses (13). Infantile spasm was found 
to be associated with intractable epilepsy in univariate 
analysis, in agreement with the findings of Chawla et 
al. and Berg et al. (10,14), but this association was not 
retained in the multivariate analysis. Similarly, mental 
retardation was observed in 70.42% of intractable patients 
compared to 23.5% of well-controlled patients, but a 
significant association was obtained only by univariate 
analysis. Univariate comparisons between the 2 groups 
suggested that abnormal neurological development and 
mental status were relatively important predictive factors, 
in accordance with previous papers (2,4,7,10,14), but 
neither was significant by multivariate analysis. History 
of neonatal seizures is considered an important predictor 
of intractability (11,14). In contrast, status epilepticus was 
not found to be an important predictive factor in our study, 
although there are contradictory reports in the literature. 
This raises the question of whether status epilepticus is a 
result or a cause of epilepsy. A history of febrile seizures 
was also unrelated to intractability in this study (2,14). 
Similarly, neither Sillanpaa (7) nor Chawla et al. (10) found 
a significant association between febrile seizures and drug-
refractory status.
Abnormal brain imaging findings, which can often 
reveal the immediate causes of seizures, were observed 
in 50% of the intractable group but in less than 20% of 
the drug-responsive patients. Although significant on 
univariate analysis, again an abnormal brain imaging result 
was not significant on multivariable analysis. Perinatal 
causes, including hypoxic-ischemic encephalopathy (HIE) 
and hypoglycemia, as well as stroke, central nervous system 
(CNS) infection sequelae, mesial temporal sclerosis, 
cortical dysplasia, and neurocutaneous disease, were found 
in both the intractable and the controlled group, (2,10) but 
none were statistically associated with one group or the 
other given the small number of intractable patients.
It is well known that the most important cause of 
intractable epileptic foci is mesial temporal sclerosis 
(MTS) and that MTS is the best target for epilepsy surgery. 
In our study, only one patient was diagnosed with mesial 
temporal sclerosis. In accord with previous findings, 
perinatal HIE was the most common underlying disorder 
in our patents with symptomatic intractable epilepsy.
This study demonstrates that high initial seizure 
frequency and symptomatic etiology are significant and 
independent predictors of drug-refractory epilepsy in 
Turkish children. Indeed, our study suggests that the 
risk of developing intractable epilepsy can be predicted 
to some degree by the early course of the illness. Early 
identification of high-risk patients will guide appropriate 
treatments while avoiding the use of potentially dangerous 
and inefficacious AEDs.
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